UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preparing for a paradigm shift in the treatment of ovarian cancer: Effect of online CME on oncologists' knowledge and competence

Gynecologic oncology, 2016-06, Vol.141, p.156-156

2016

Volltextzugriff (PDF)

Sexual Dysfunction After Cancer: Findings From the Program in Women’s Oncology Center for Sexuality, Intimacy, and Fertility

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E487-E487

2015

Volltextzugriff (PDF)

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva

Gynecologic oncology, 2012-10, Vol.127 (1), p.141-146

2012

Volltextzugriff (PDF)

Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5943-5949

2005

Volltextzugriff (PDF)

Sexual Function, Quality of Life (QOL), and Mood After Radiation Therapy in Patients With Anal Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E533-E533

2016

Volltextzugriff (PDF)

A prospective phase II trial of the listeria-based human papillomavirus immunotherpay axalimogene filolisbac in second- and third-line metastatic cervical cancer: A NRG oncology group trial

Gynecologic oncology, 2017-06, Vol.145, p.220-220

2017

Volltextzugriff (PDF)

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer

Gynecologic oncology, 2016-04, Vol.141 (1), p.108-112

2016

Volltextzugriff (PDF)

Clinical Needs Assessment for Sexual Health Among Cancer Patients Receiving Pelvic Radiation

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E528-E529

2016

Volltextzugriff (PDF)

Dose delay, but not dose reduction, in chemotherapy administration is associated with decreased survival in elderly women with ovarian cancer

Gynecologic oncology, 2014-06, Vol.133, p.32-32

2014

Volltextzugriff (PDF)

44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas

Annals of oncology, 2022-05, Vol.33, p.S142-S142

2022

Volltextzugriff (PDF)

Management and outcomes for elderly women with vulvar cancer over time

Gynecologic oncology, 2014-06, Vol.133, p.154-155

2014

Volltextzugriff (PDF)

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i4-i10

2016

Volltextzugriff (PDF)

594P The heterogeneic molecular landscape of ovarian cancer metastases (OCM)

Annals of oncology, 2022-09, Vol.33, p.S818

2022

Volltextzugriff (PDF)

Longitudinal Follow-up of Women who received Pelvic Radiation for Lower GI or Gynecologic Cancers

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E559-E559

2019

Volltextzugriff (PDF)

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

Annals of oncology, 2017-03, Vol.28 (3), p.505-511

2017

Volltextzugriff (PDF)

Reply to the letter to the editor ‘Integrating communication as a core skill in the global curriculum for medical oncology’ by Horlait et al

Annals of oncology, 2017-04, Vol.28 (4), p.905-906

2017

Volltextzugriff (PDF)

A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer

Annals of oncology, 2018-10, Vol.29, p.viii334-viii335

2018

Volltextzugriff (PDF)

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Gynecologic oncology, 2019-05, Vol.153 (2), p.223-229

2019

Volltextzugriff (PDF)

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

Gynecologic oncology, 2018-06, Vol.149, p.24-24

2018

Volltextzugriff (PDF)

Results of Gynecologic Oncology Group (GOG) 229K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma

Gynecologic oncology, 2014-06, Vol.133, p.55

2014

Volltextzugriff (PDF)

Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P

Gynecologic oncology, 2018-06, Vol.149, p.12-13

2018

Volltextzugriff (PDF)

Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

Gynecologic oncology, 2018-06, Vol.149, p.24-25

2018

Volltextzugriff (PDF)

Results of Gynecologic Oncology Group (GOG) 229 K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma

Gynecologic oncology, 2014-06, Vol.133, p.55-55

2014

Volltextzugriff (PDF)

Chapter 9 - Novel Chemotherapy Tools: Intraperitoneal Therapy, Dose-Dense Therapy

Translational Advances in Gynecologic Cancers, 2017, p.171-180

Dizon, D.S.

2017

Volltextzugriff (PDF)

Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumor malignancies

European journal of cancer (1990), 2001-04, Vol.37, p.S77-S77

2001

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)
Buchkapitel
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Preparing for a paradigm shift in the treatment of ovarian cancer: Effect of online CME on oncologists' knowledge and competence

Sexual Dysfunction After Cancer: Findings From the Program in Women’s Oncology Center for Sexuality, Intimacy, and Fertility

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva

Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer

Sexual Function, Quality of Life (QOL), and Mood After Radiation Therapy in Patients With Anal Cancer

A prospective phase II trial of the listeria-based human papillomavirus immunotherpay axalimogene filolisbac in second- and third-line metastatic cervical cancer: A NRG oncology group trial

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer

Clinical Needs Assessment for Sexual Health Among Cancer Patients Receiving Pelvic Radiation

Dose delay, but not dose reduction, in chemotherapy administration is associated with decreased survival in elderly women with ovarian cancer

44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas

Management and outcomes for elderly women with vulvar cancer over time

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer

594P The heterogeneic molecular landscape of ovarian cancer metastases (OCM)

Longitudinal Follow-up of Women who received Pelvic Radiation for Lower GI or Gynecologic Cancers

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

Reply to the letter to the editor ‘Integrating communication as a core skill in the global curriculum for medical oncology’ by Horlait et al

A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

Results of Gynecologic Oncology Group (GOG) 229K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma

Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P

Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

Results of Gynecologic Oncology Group (GOG) 229 K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma

Chapter 9 - Novel Chemotherapy Tools: Intraperitoneal Therapy, Dose-Dense Therapy

Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumor malignancies

Suchergebnisse filtern